ORIC Pharmaceuticals, Inc. ORIC R2KR3KPHARMA
Company Overview
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +30.82% |
| 6 Months: | -6.20% |
| 3 Months: | +71.47% |
| 1 Month: | -0.54% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)48.86 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ORIC ORIC Pharmaceuticals, Inc. R2KR3KPHARMA | 12.86 | -9.89 | $1.33B | 0.00% | -36.81% | -39.80% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -6.35M | -6.36M | -7.10M | -9.18M | -11.12M | -25.60M | -16.55M | -21.06M | -18.46M | -23.26M | -20.70M | -25.69M | -25.68M | -24.99M | -28.68M | -28.99M | -36.02M | -38.32M | -32.72M | -39.06M | -36.67M | -39.62M | -45.30M |
| Net Income | -6.01M | -5.96M | -6.55M | -8.87M | -11.02M | -25.55M | -16.51M | -21.01M | -18.43M | -23.16M | -20.29M | -24.83M | -23.95M | -22.94M | -25.48M | -25.01M | -31.96M | -34.57M | -30.02M | -36.35M | -32.59M | -35.77M | -41.49M |
| Diluted EPS | - | - | - | - | - | - | - | -0.57 | -0.47 | -0.59 | -0.51 | -0.63 | -0.53 | -0.50 | -0.44 | -0.37 | -0.45 | -0.49 | -0.42 | -0.47 | -0.33 | -0.34 | -0.38 |
| R&D Expense | 5.21M | 5.04M | - | 7.25M | 7.72M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Income | -22.37M | -28.57M | -74.19M | -78.87M | -91.77M | -110.78M | -142.90M | -143.00M |
| Net Income | -21.36M | -26.88M | -73.70M | -78.72M | -89.12M | -100.70M | -127.85M | -129.47M |
| Diluted EPS | - | - | - | -2.07 | -2.25 | -1.96 | -1.83 | -1.47 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 94.09M | 299.00M | 298.64M | 247.18M | 252.01M | 274.14M | 408.89M |
| Total Equity | -43.61M | -64.43M | -90.08M | 289.78M | 272.98M | 222.35M | 224.09M | 243.12M | 384.36M |
| Cash & Equivalents | - | - | 89.16M | 78.45M | 226.01M | 66.84M | 23.38M | 59.41M | 45.67M |
| Long Term Debt | - | - | - | - | 10.50M | - | - | - | - |
| Total Liabilities | - | - | 6.12M | 9.22M | 25.67M | 24.83M | 27.92M | 31.02M | 24.53M |
| Current Liabilities | - | - | 5.35M | 9.00M | 15.15M | 15.39M | 20.46M | 24.85M | 20.42M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -20.68M | -23.53M | -45.27M | -59.54M | -75.14M | -85.69M | -112.66M | -110.97M |
| Investing Cash Flow | -508.00K | -768.00K | -215.96M | 158.44M | -109.25M | -43.40M | 22.14M | -148.03M |
| Financing Cash Flow | 38.01M | 70.82M | 250.51M | 49.13M | 25.23M | 85.66M | 126.55M | 245.26M |
| Capital Expenditure | -525.00K | -768.00K | -667.00K | -939.00K | -2.08M | -849.00K | -1.19M | -712.00K |
| Free Cash Flow | -21.21M | -24.30M | -45.94M | -60.48M | -77.22M | -86.54M | -113.85M | -111.68M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - |
| ROE % | 33.2% | 29.8% | -25.4% | -28.8% | -40.1% | -44.9% | -52.6% | -33.7% |
| ROCE % | - | -32.2% | -25.6% | -27.8% | -39.6% | -47.8% | -57.3% | -36.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Nextech Invest, Ltd. | 6.91% | 7.16M | $94.83M |
| 2 | Blackrock Inc. | 6.58% | 6.82M | $90.35M |
| 3 | EcoR1 Capital, LLC | 6.49% | 6.73M | $89.08M |
| 4 | Price (T.Rowe) Associates Inc | 6.38% | 6.62M | $87.62M |
| 5 | Viking Global Investors, L.P. | 4.95% | 5.13M | $67.88M |
| 6 | State Street Corporation | 4.72% | 4.89M | $64.80M |
| 7 | SR One Capital Management, LP | 4.45% | 4.62M | $61.11M |
| 8 | Venrock Adviser, LLC | 4.17% | 4.32M | $57.19M |
| 9 | NEA Management Company, LLC | 3.97% | 4.12M | $54.53M |
| 10 | Vanguard Capital Management LLC | 3.81% | 3.95M | $52.31M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ORIC
ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQdkRaQ3VJZURmaVhDSUlPekNHVnRNblJkdVVRSmFybmZUb2MydUcxWm16ZHpTYV9LTGU1VnRRdEkxMkltZDVDNFJjWlhGNkktMFZWcTZRNGhXLTJXYTlBMUkxcm1yMVVIU3lWb1dIdDBReUw1eE5lLTc2VFQ2dkhvYnFBSDJWRDN4Q0ZFYk…
Enterprise value to revenue forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQOEtKV2hQNUlXV0dMZlhvR1dyUjc4NF9nTjRSNUtFUm8taW9Tekd0U3ByTDMzS2dqT3BCU2FoVENIYTR3Nk1fUUpVT19HVDhqbE1UMVVLV3BERUMyUkFXNnpKWmszS2p5c3FqUW13d0RyaG83eEN1ejRpendCUVRHLUVUMi1kWERwY21tV2…
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQa2c4YXgzWW1CZGd2U0hNM19CWkszR2UzdjJueU1kZXhfSFVwRDlxTHJzbkF6LUxMTXFFVTlfb290ai1tR052aWRJaUlUU1dIenNJVG9MY1NsSS1PYTlnNDI2NWh4bDU4UWFPUDVCelRXa0hjZXFYVllnV2lReTlfV0llODgzUHFxTEkydU…
Morgan Stanley's healthcare conference is one of three where ORIC management will speak. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxNOGU2Ym10WUphNnBHdTFzbjRHZTBuajRQcVBqdGNmMXVMcjFPR2thaHlVb3lYRTlCNnNJMVZTRUxqbkUzM1lrNFZkRzZqRDdkZUN4ai01NjFjNG1PbVNQVm5yZFV5bGdyYjRybGZidlljNExPZFJKQVFUckJiek0yYzRuanhJRlpoT0RaYW…
$ORIC stock is up 13% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPZ21WcEVGaEM1cWgwaGQ4UGZYRTU0dzl4eDNJdk0xQ1JJOHhqWm9pRkszSjR0TDBDeHhqdFNwOW9JLU5reWxsWTVaQ3hka1FvdHBQTFNvejlBcjRuMG5yMEFzbDFuS0dRNjU0d0drOHZSZGhObFAtSWY2Mng0dWh1N2d3S3hRQ1c3VGhDY2…
Oric chases Pfizer into phase 3 hailing prostate cancer edge, but investors send stock down - Fierce Biotech
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZE1XVzNxdTNUV1hBelFuLVBwM21GTUZSdDJGX2lnN2hJQnFVVEZtNFdNUVJnSS1VcC1XYWdnVjFwb3JwWVc3a2lOWVlkWUZhNXhacER3RWd5UjAwbFBydXBQTml6SUdVcHEyX1VoakFaYWowMktJbjd4SjYtWFJaSlREUmxRX1ZaQnF1c0…
ORIC — Frequently Asked Questions
What is the current share price of ORIC Pharmaceuticals, Inc. (ORIC)?
As of 2026-09-07 16:24 PDT, ORIC Pharmaceuticals, Inc. (ORIC) trades at $12.86 on NasdaqGS. Its 52-week range is $7.48 to $14.65.
What is the market capitalisation of ORIC?
ORIC Pharmaceuticals, Inc. (ORIC) has a market capitalisation of $1.33B on NasdaqGS.
What is the P/E ratio of ORIC?
ORIC trades at a trailing price-to-earnings (P/E) ratio of -9.89. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.36.
What is the return on equity (ROE) of ORIC?
ORIC has a return on equity (ROE) of -39.80%. Its return on capital employed (ROCE) is -36.81%.
Is ORIC a good stock to buy?
This page provides a data-driven analysis of ORIC Pharmaceuticals, Inc. (ORIC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.